APA (7th ed.) Citation

K, A., V, D., M, L., F, S., S, S., & AA, A. (2026). Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States. Clinical drug investigation, 46(7), 721. https://doi.org/10.1007/s40261-026-01560-0

Chicago Style (17th ed.) Citation

K, Adjei, Diaby V, Li M, Sherbeny F, Suther S, and Ali AA. "Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States." Clinical Drug Investigation 46, no. 7 (2026): 721. https://doi.org/10.1007/s40261-026-01560-0.

MLA (9th ed.) Citation

K, Adjei, et al. "Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States." Clinical Drug Investigation, vol. 46, no. 7, 2026, p. 721, https://doi.org/10.1007/s40261-026-01560-0.